Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Share-based Compensation for 5 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 3.05% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.5 million through Dec 2025, up 10.97% year-over-year, with the annual reading at $54.5 million for FY2025, 10.97% up from the prior year.
  • Share-based Compensation hit $13.8 million in Q4 2025 for Krystal Biotech, up from $13.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.1 million in Q2 2025 to a low of $2.3 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $9.6 million across 5 years, with a median of $9.7 million in 2022.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 177.99% in 2022 and later dropped 10.9% in 2024.
  • Year by year, Share-based Compensation stood at $5.1 million in 2021, then skyrocketed by 85.66% to $9.6 million in 2022, then increased by 3.15% to $9.9 million in 2023, then soared by 35.55% to $13.4 million in 2024, then increased by 3.05% to $13.8 million in 2025.
  • Business Quant data shows Share-based Compensation for KRYS at $13.8 million in Q4 2025, $13.2 million in Q3 2025, and $14.1 million in Q2 2025.